Awards Nomination 20+ Million Readerbase
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Flyer image
Design and synthesis of potent Cyclin C inhibitors
3rd World Congress Bioavailability & Bioequivalence
March 26-28, 2012 Marriott Hotel & Convention Centre, Hyderabad, India

Sarita Rajender P., Kiran Kumar Mustyala, Bhargavi Kondagari, Vasavi Malkhed and Uma Vuruputuri

Scientific Tracks Abstracts: J Bioequiv Availab

Abstract:

T he fundamental aspect of cancer is deregulated cell replication leading to tumour formation. Alterations result in the inappropriate proliferation of the apparatus that controls the decision of cells to progress from (G0-G1) resting phase or G1 to S phase leading to tumours (1). Cyclin C is an attractive target operating in G0 ? G1 phase of the cell cycle which combines with CDK8/Cdk3 leading to cell division (2). The structure of cyclin C has been evaluated by homology modeling, energy minimised and its active site identified (3). Virtual Screening with CB micro format data bank using Schrodinger Software resulted in a set of novel leads as potent inhibitors for cyclin C protein. The new molecular entities were ascertained based on the Glide score function and QikProp (ADME) properties as substituted barbiturates. Substituted barbiturates are one of the most important structural class of anti-tumour compounds. These compounds act by inhibiting the combination of Cyclin C with CDK3/8 Kinases (3). Further, these chemical entities were synthesised and their cytotoxic studies were performed on HEK 293 cell lines. The new molecular entities have shown promising growth inhibitory (GI) effects

Biography :

Dr. P. Sarita Rajender, is a DST ? Scientist at The Department of Chemistry, Nizam College, Osmania University since 2009 and has completed Ph. D in Synthetic Organic Chemistry in the year 1996. She is a post-doctoral research fellow working on novel platforms for finding new leads in Cancer therapy. Patenting process is under progress for promising new lead molecules. Her field of research interest includes identification of new chemical entities (NCE?s) using Computational Chemistry, Chemical-Biology and Software tools. During her teaching tenure, she has mentored PG students in their dissertation work. She is actively organizing Seminars and workshops for students. Dr. P. Sarita Rajender published several research articles in reputed international journals and has presented papers at various International and National Conferences